Solu-Moderín 125 mg polvo y disolvente para solución inyectable clinical trials

A 2-Part, Multicenter, Randomized, Blinded, Active-Controlled Phase 2 Study to Sequentially Evaluate the Safety and Efficacy of BIIB091 Monotherapy and BIIB091 Combination Therapy With Diroximel Fumarate in Participants With Relapsing Forms of Multiple Sclerosis

This study is looking at a new medicine, BIIB091, for people with relapsing forms of multiple sclerosis (MS). It will check how safe it is and how well it works, both on its own and when given with another MS medicine called Vumerity.